458-40-2

Basic information

• Product Name: 2-(3-fluoro-4-methoxyphenyl)ethanamine
• Synonyms: 2-(3-fluoro-4-methoxyphenyl)ethanamine;2-(3-FLUORO-4-METHOXYPHENYL)ETHAN-1-AMINE;2-(3-fluoro-4-methoxyphenyl)ethanamine(Hydrochloride form)
• CAS NO: 458-40-2
• Molecular Formula: C₉H₁₂FNO
• Molecular Weight: 169.1960832
• Mol File: 458-40-2.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(3-fluoro-4-methoxyphenyl)ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-fluoro-4-methoxyphenyl)ethanamine(458-40-2)
• EPA Substance Registry System: 2-(3-fluoro-4-methoxyphenyl)ethanamine(458-40-2)

Safety Data

• Hazardous Substances Data: 458-40-2(Hazardous Substances Data)

Usage

Classification

Ethylamine derivative

Usage

Synthesis of various pharmaceuticals in medicinal chemistry

Contains fluoro and methoxy groups on the phenyl ring

May confer specific pharmacological properties

Safety

Handle with care and in accordance with proper safety protocols to avoid health and environmental hazards

Upstream product

• 404-90-0 2-(3-fluoro-4-methoxyphenyl)acetonitrile 
• 351-52-0 3-fluoro-4-methoxybenzyl chloride 
• 118958-80-8 (trans)-2-fluoro-1-methoxy-4-(2-nitrovinyl)benzene 
• 351-54-2 3-fluoro-p-anisaldehyde 
• 118958-80-8 2-fluoro-1-methoxy-4-(2-nitrovinyl)benzene 

Downstream Products

• 128495-61-4 N-propionyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-88-6 N,N-diethyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 857252-16-5 N,N-diethyl-N'-[2-(3-fluoro-4-methoxyphenyl)ethyl]terephthalamide 
• 885066-01-3 (6-chloro-2-methoxy-pyrimidin-4-yl)-[2-(3-fluoro-4-methoxy-phenyl)-ethyl]-amine 
• 128495-69-2 N-n-propyl-N-(2-phenylethyl)-2-(3-fluoro-4-hydroxyphenyl)ethylamine hydrobromide 
• 128495-62-5 N-n-propyl-N-(phenylacetyl)-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 128495-63-6 N-n-propyl-N-(2-phenylethyl)-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-85-3 N-ethyl-N-propionyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-84-2 N-methyl-N-propionyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-83-1 N-methyl-N-acetyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-92-2 N-ethyl-N-n.propyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 

Relevant articles and documents

6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER

The present invention discloses 6,7-dihydro-5H-pyrido[2,3- c]pyridazine, 1,2,3,4-tetrahydroquinoline, 1H-indole, 3,4- dihydro-2H-1,4-benzoxazine, 1H-pyrrolo[2,3-b]pyridin-1-yl, 7H- pyrrolo[2,3-c]pyridazine, 5H,6H,7H,8H,9H-pyridazino[3,4-b]azepine derivatives and related compounds of formula (I) as Bcl-xL protein inhibitors for use as pro-apoptotic agents for treating cancer, autoimmune diseases or immune system diseases. Formula (I). The description discloses the preparation of exemplary compounds (e.g. pages 113 to 354 examples 1 to 221) as well as pharmacological studies with relevant data (e.g. pages 355 to 367; examples A to E; tables 1 to 5). Exemplary compounds are e.g. 2-{6-[(1,3-benzothiazol-2-yl) amino]-1,2,3,4-tetrahydroquinolin-1-yl}-1,3-thiazole-4-carboxylic acid (example 1) or e.g. 3-{1-[(adamantan-1-yl)methyl]-5- methyl-1H-pyrazol-4-yl}-6-{3-[(1,3-benzothiazol-2-yl)amino]-4- methyl-5H,6H,7H,8H-pyrido[2,3-c]pyridazin-8-yl]pyridine-2-carboxylic acid (example 24).

DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.